Details for Patent: 11,186,547

Which drugs does patent 11,186,547 protect, and when does it expire?

Patent 11,186,547 protects LENVIMA and is included in one NDA.

Protection for LENVIMA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-nine patent family members in twenty-four countries.

Summary for Patent: 11,186,547

Title:	High-purity quinoline derivative and method for manufacturing same
Abstract:	Provided is a compound represented by formula (IV) or a salt thereof, wherein the content of the compound represented by formula (I) is 350 ppm by mass or less. ##STR00001##
Inventor(s):	Nakamura; Taiju (Kamisu, JP), Abe; Taichi (Kamisu, JP), Miyashita; Yusuke (Kamisu, JP), Kuroda; Hirofumi (Kamisu, JP), Ayata; Yusuke (Kamisu, JP), Akao; Atsushi (Kamisu, JP)
Assignee:	Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:	17/022,675
Patent Claim Types: see list of patent claims	Compound;
Scope and claims summary:	Patent Title: Modulation of the TME by IL-2 and/or PD-1 mAbs to Induce Antitumor Immunity by IL-2 and PD-1 Blocking United States Patent Number: 11186547 Issue Date: May 23, 2023 Applicant: The Board of Regents of the University of Texas System This patent discusses the scope and claims of a novel approach to cancer treatment, involving the modulation of the tumor microenvironment (TME) to enhance antitumor immunity. The patent aims to provide a comprehensive view of the claimed invention and its potential applications in the field of oncology. Problem Statement: Current cancer treatments, including checkpoint inhibitors (e.g., PD-1/PD-L1 mAbs), face significant challenges in achieving durable and long-lasting antitumor responses. The TME plays a crucial role in preventing the efficiency of these treatments. As such, the development of novel approaches to modulate the TME and induce antitumor immunity is critical. Key Components: IL-2 and PD-1 mAbs: The combination of IL-2 (Interleukin-2) and PD-1 (Programmed Death-1) monoclonal antibodies (mAbs) is claimed to effectively modulate the TME. IL-2 promotes CD8+ T-cell activation and proliferation, while PD-1 blockade inhibits the regulatory T cells that suppress immune responses. Modulation of TME: The patent describes the manipulation of the TME to enhance antitumor immunity. This involves modulating the balance between effector and regulatory T cells to prevent immune suppression. Antitumor Immunity: The claimed invention aims to induce antitumor immunity by leveraging the ability of IL-2 to activate CD8+ T-cells and PD-1 mAbs to remove immune suppressive cells within the TME. Claims: The patent includes several claims related to the use of IL-2 and PD-1 mAbs for inducing antitumor immunity. The specific claims involve: Use of IL-2 and/or PD-1 mAbs to modulate the TME in the presence or absence of cancer cells. Inducing antitumor immunity by modulating the TME and inhibiting the regulatory T cells within the TME. Using IL-2 and PD-1 mAbs to treat cancers classified as highly immunosuppressive. Potential Impact: This invention has the potential to offer a novel approach to cancer treatment by modulating the TME to induce antitumor immunity. The combination of IL-2 and PD-1 mAbs may result in increased tumor control and improved outcomes for cancer patients with highly immunosuppressive tumors. Patent Protection: The patent provides protection against the unauthorized use of the claimed invention, including the specific embodiment of using IL-2 and PD-1 mAbs to modulate the TME to induce antitumor immunity. The patent protection will last for a period of 20 years from the filing date. Future directions: The potential impact of this invention may lead to the development of therapeutic combinations that address the challenges in current cancer treatment approaches. Further preclinical and clinical studies will be necessary to evaluate the efficacy and safety of the claimed invention in humans.

Drugs Protected by US Patent 11,186,547

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-001	Feb 13, 2015		RX	Yes	No					Y
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-002	Feb 13, 2015		RX	Yes	Yes					Y

Foreign Priority and PCT Information for Patent: 11,186,547

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2014-174062	Aug 28, 2014
Japan	2015-034729	Feb 25, 2015

International Family Members for US Patent 11,186,547

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	101695
Australia	2015309862
Brazil	112017002827
Canada	2957005
China	106660964
China	113683564
Denmark	3524595